GoodRx Holdings, Inc. (GDRX) Bundle
An Overview of GoodRx Holdings, Inc. (GDRX)
General Summary of GoodRx Holdings, Inc.
GoodRx Holdings, Inc. (GDRX) was founded in 2011 with the mission to help Americans obtain healthcare at affordable prices. The company provides a platform that offers price comparisons for prescription medications, allowing consumers to find the best prices at local pharmacies. GoodRx's services include prescription transaction revenue, subscription plans, and solutions for pharmaceutical manufacturers. As of 2024, GoodRx has seen a notable increase in its user base, with over 7 million prescription-related consumers utilizing its services.
Company's Financial Performance in the Latest Financial Reports
In the latest financial report for the third quarter of 2024, GoodRx reported:
- Revenue: $195.3 million, an increase of 8% from $180.0 million in Q3 2023.
- Adjusted Revenue: $195.3 million, up 3% from $190.0 million in the same period last year.
- Net Income: $4.0 million, with a net income margin of 2.0%, compared to a net loss of $38.5 million and a margin of -21.4% in Q3 2023.
- Adjusted EBITDA: $65.0 million, representing a margin of 33.3%, compared to $53.5 million and a margin of 28.1% in Q3 2023.
For the nine months ending September 30, 2024, GoodRx reported:
- Revenue: $593.7 million, an increase of 7% from $553.6 million in the same period of 2023.
- Net Income: $9.7 million, with a margin of 1.6%, down from $17.0 million and 3.1% margin in 2023.
- Adjusted EBITDA: $193.2 million, with a margin of 32.5%, compared to $160.2 million and a margin of 28.4% in 2023.
The company's revenue sources for Q3 2024 included:
| Revenue Source | Q3 2024 Revenue (in thousands) | Q3 2023 Revenue (in thousands) | Change (%) |
|---|---|---|---|
| Prescription Transactions | $140,419 | $135,427 | 4% |
| Subscription Revenue | $21,306 | $23,240 | -8% |
| Pharma Manufacturer Solutions | $28,136 | $15,897 | 77% |
| Other Revenue | $5,390 | $5,394 | 0% |
Introduction to Company as a Leader in the Industry
GoodRx Holdings, Inc. is recognized as a leading company in the digital healthcare space, particularly in prescription pricing and consumer savings. The company's innovative platform has effectively captured a significant share of the market, driven by a consistent increase in Monthly Active Consumers, which rose by 8% year-over-year. Moreover, GoodRx's adaptation to market changes and its capacity to expand its services reflect its strong positioning in an evolving industry landscape. To understand more about why GoodRx is successful, further insights into its operational strategies and market engagement can be explored below.
Mission Statement of GoodRx Holdings, Inc. (GDRX)
Mission Statement of GoodRx Holdings, Inc. (GDRX)
GoodRx Holdings, Inc. operates with a mission to help Americans get the healthcare they need at a price they can afford. This mission emphasizes the company's commitment to making healthcare accessible and affordable for consumers. In 2024, GoodRx continues to build the leading consumer-focused digital healthcare platform in the United States, reflecting its strategic focus on meeting the diverse needs of its users.
Core Component 1: Accessibility
The first core component of GoodRx's mission statement is accessibility. GoodRx aims to ensure that all consumers can access necessary medications and healthcare services without the burden of high costs. As of September 2024, GoodRx reported over 7 million prescription-related consumers utilizing its platform, demonstrating the significant demand for its offerings. The company’s user-friendly platform allows consumers to easily find and compare prices for medications, thus promoting informed healthcare choices.
| Key Metrics | September 2024 | September 2023 | Change (%) |
|---|---|---|---|
| Monthly Active Consumers | 6.5 million | 6.1 million | 8% |
| Prescription Transactions Revenue | $432.6 million | $406.9 million | 6% |
| Subscription Revenue | $65.9 million | $71.3 million | (8%) |
Core Component 2: Affordability
The second component focuses on affordability. GoodRx provides tools that help consumers save money on prescriptions. The company's platform enables users to compare prices from various pharmacies, and its discounts can significantly lower out-of-pocket costs. In the third quarter of 2024, GoodRx achieved a revenue of $195.3 million, an increase of 8% from $180.0 million in the same quarter of the previous year. This growth indicates a rising demand for cost-saving solutions in the healthcare sector.
Core Component 3: Consumer Empowerment
The third core component is consumer empowerment. GoodRx empowers consumers by providing transparent pricing and access to healthcare services. The platform's design encourages users to take control of their healthcare decisions, thereby fostering a more informed consumer base. The adjusted EBITDA margin for the third quarter of 2024 was 33.3%, compared to 28.1% in the previous year, signifying improved operational efficiency and capacity to reinvest in consumer-focused initiatives.
| Financial Performance Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Income | $4.0 million | $(38.5 million) | N/A |
| Adjusted EBITDA | $65.0 million | $53.5 million | 21% |
| Adjusted EBITDA Margin | 33.3% | 28.1% | 5.2% |
GoodRx’s mission statement encapsulates the company's dedication to enhancing healthcare accessibility, affordability, and consumer empowerment, aligning with its operational strategies and financial performance as of 2024. The ongoing commitment to these principles positions GoodRx as a key player in the digital healthcare landscape, responding to the needs of American consumers effectively.
Vision Statement of GoodRx Holdings, Inc. (GDRX)
Vision Statement Overview
The vision statement of GoodRx Holdings, Inc. (GDRX) emphasizes their commitment to making healthcare accessible and affordable for all Americans. This vision reflects their goal to be the leading consumer-focused digital healthcare platform in the U.S.
Consumer Empowerment
GoodRx aims to empower consumers by providing transparent pricing and access to medications. This initiative is evidenced by their growth in Monthly Active Consumers, which reached over 7 million by September 2024, marking an increase of 8% year-to-date compared to the previous year.
Innovation in Healthcare
The company is focused on innovative solutions that enhance the healthcare experience. GoodRx's revenue from prescription transactions increased by 4% year-over-year, totaling $140.4 million for the three months ended September 30, 2024. This growth illustrates their commitment to integrating new technologies and services into their offerings.
Partnerships with Pharma Manufacturers
GoodRx is expanding its partnerships with pharmaceutical manufacturers to improve service offerings. The revenue from their pharma manufacturer solutions surged by 77%, reaching $28.1 million for the same quarter. This indicates a strategic focus on collaboration to enhance product accessibility and consumer savings.
Financial Performance and Sustainability
GoodRx’s financial metrics reflect their operational efficiency and commitment to sustainability. For the three months ended September 30, 2024, the company reported total revenue of $195.3 million, an increase of 8% from the previous year. Their Adjusted EBITDA margin improved to 33.3%, highlighting a focus on profitability.
Commitment to Affordability
GoodRx continues to prioritize affordability in healthcare. The company has been instrumental in helping consumers save on prescription costs, with total savings estimated at billions annually. Their platform's ability to provide lower-priced alternatives is an essential aspect of their vision.
| Financial Metrics | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenue | $195.3 million | $179.96 million | $15.34 million | 8% |
| Prescription Transactions Revenue | $140.4 million | $135.4 million | $5 million | 4% |
| Pharma Manufacturer Solutions Revenue | $28.1 million | $15.9 million | $12.2 million | 77% |
| Net Income | $3.97 million | $(38.5) million | $42.47 million | n/a |
| Adjusted EBITDA Margin | 33.3% | 28.1% | 5.2% | n/a |
Future Outlook
Looking ahead, GoodRx is poised to continue its trajectory of growth and innovation within the healthcare sector. Their vision incorporates ongoing advancements in technology and partnerships, which are expected to enhance consumer engagement and streamline healthcare access. The strategic focus on affordability and transparency will remain central to their operations as they adapt to the evolving healthcare landscape.
Core Values of GoodRx Holdings, Inc. (GDRX)
Integrity
The core value of integrity at GoodRx Holdings, Inc. (GDRX) emphasizes transparency, honesty, and ethical behavior in all business dealings. This commitment is crucial for maintaining trust with consumers, partners, and stakeholders.
In 2024, GoodRx has demonstrated this value through the implementation of robust compliance programs and transparent communication regarding pricing. For instance, the company has maintained a policy of clearly disclosing its pricing structure and potential savings to consumers, ensuring that users understand the benefits of using its platform.
Customer Focus
Customer focus is central to GoodRx's operations, driving the company to prioritize the needs and experiences of its users. This value underpins the development of user-friendly tools and services that enhance the healthcare experience.
As of September 30, 2024, GoodRx reported having over 7 million prescription-related consumers utilizing its services, reflecting a year-over-year increase in Monthly Active Consumers by approximately 8%. The company continually seeks feedback from users to refine its offerings, including its subscription plans, which saw a decline to 701 thousand active plans due to the sunset of the Kroger Savings program.
Innovation
Innovation at GoodRx is about leveraging technology to improve healthcare access and affordability. The company invests significantly in product development and technology to enhance its platform and services.
In the first nine months of 2024, GoodRx's product development and technology expenses amounted to $92 million, representing a decrease of 11% from the previous year, indicating a strategic focus on efficiency while continuing to innovate. The company's investments in technology aim to streamline prescription transactions and enhance user engagement through improved digital tools.
Collaboration
Collaboration is key to GoodRx's approach, fostering partnerships with pharmacies, healthcare providers, and pharmaceutical manufacturers to create a more integrated healthcare solution.
In 2024, GoodRx's revenue from pharma manufacturer solutions increased by 77% year-over-year, reaching $79 million. This growth reflects the company's success in building collaborative relationships that enhance service offerings and expand market reach.
Accountability
Accountability at GoodRx means taking responsibility for actions and decisions, which is vital for building credibility and trust within the healthcare ecosystem.
In 2024, GoodRx has focused on improving its financial performance, reporting a net income of $9.7 million for the nine months ended September 30, 2024. The company has also actively managed its costs, with total operating expenses decreasing by 3% year-over-year, reflecting a commitment to financial discipline and accountability.
| Core Value | Key Performance Indicator | 2024 Performance |
|---|---|---|
| Integrity | Transparency in pricing | Clear disclosure of savings to consumers |
| Customer Focus | Monthly Active Consumers | 7 million (8% increase YoY) |
| Innovation | Product Development Expenses | $92 million (11% decrease YoY) |
| Collaboration | Pharma Manufacturer Solutions Revenue | $79 million (77% increase YoY) |
| Accountability | Net Income | $9.7 million (for 9 months ended Sep 30, 2024) |
GoodRx Holdings, Inc. (GDRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- GoodRx Holdings, Inc. (GDRX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of GoodRx Holdings, Inc. (GDRX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View GoodRx Holdings, Inc. (GDRX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.